You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company, known for providing hereditary risk testing for cancer and cardiovascular conditions, has expanded into SARS-CoV-2 testing.
The test was first authorized in May for the detection of the SARS-CoV-2 N, E, and ORF1a genes in nasopharyngeal swabs and other specimens.
Color Genomics' kit is designed for the unmonitored self-collection of nasal swab specimens for SARS-CoV-2 testing.
Accounting for polygenic background in conditions like hereditary breast cancer or Lynch syndrome can increase the accuracy of disease risk estimation.
Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.
The next iteration of Ancestry's Health experience seeks to provide customers with actionable information about certain commonly inherited health conditions.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
Working with clinical decision support vendor ActX, the suburban Chicago health system has seen strong demand for PGx and genetically informed preventive care.
The MAGENTA and ProGen trials showed that video-based and online education can increase the number of patients getting tested compared to traditional approaches.
23andMe has launched a new tool that estimates someone's risk of developing severe COVID-19 if infected, Bloomberg reports.
The Guardian reports that Pasteur Institute researchers are halting their development of a SARS-CoV-2 vaccine following disappointing initial results.
The Wall Street Journal reports that an increased number of younger patients have been hospitalized as the new SARS-CoV-2 strain spread across the UK.
In Cell this week: proteomic patterns among COVID-19 affected tissue samples, transcriptome atlas of developing intestines, and more.